JP2011522773A - 治療剤での癌の処置方法 - Google Patents

治療剤での癌の処置方法 Download PDF

Info

Publication number
JP2011522773A
JP2011522773A JP2010540875A JP2010540875A JP2011522773A JP 2011522773 A JP2011522773 A JP 2011522773A JP 2010540875 A JP2010540875 A JP 2010540875A JP 2010540875 A JP2010540875 A JP 2010540875A JP 2011522773 A JP2011522773 A JP 2011522773A
Authority
JP
Japan
Prior art keywords
cancer
hedgehog
chemotherapeutic agent
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010540875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522773A5 (https=
Inventor
グレイゼル、デビッド
ダブリュ． ロス、ロバート
マクドゥーガル、ジョン
Original Assignee
インフィニティ ファーマスーティカルズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40824720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011522773(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/965,688 external-priority patent/US7812164B2/en
Application filed by インフィニティ ファーマスーティカルズ、インク． filed Critical インフィニティ ファーマスーティカルズ、インク．
Publication of JP2011522773A publication Critical patent/JP2011522773A/ja
Publication of JP2011522773A5 publication Critical patent/JP2011522773A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010540875A 2007-12-27 2008-12-23 治療剤での癌の処置方法 Pending JP2011522773A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1716007P 2007-12-27 2007-12-27
US11/965,688 2007-12-27
US11/965,688 US7812164B2 (en) 2006-12-28 2007-12-27 Cyclopamine analogs
US61/017,160 2007-12-27
US11896908P 2008-12-01 2008-12-01
US61/118,969 2008-12-01
PCT/US2008/088222 WO2009086416A1 (en) 2007-12-27 2008-12-23 Therapeutic cancer treatments

Publications (2)

Publication Number Publication Date
JP2011522773A true JP2011522773A (ja) 2011-08-04
JP2011522773A5 JP2011522773A5 (https=) 2012-02-16

Family

ID=40824720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010540875A Pending JP2011522773A (ja) 2007-12-27 2008-12-23 治療剤での癌の処置方法

Country Status (16)

Country Link
US (1) US20090181997A1 (https=)
EP (1) EP2225254A4 (https=)
JP (1) JP2011522773A (https=)
KR (1) KR20100137416A (https=)
CN (1) CN101918420A (https=)
AR (1) AR070047A1 (https=)
AU (1) AU2008345151A1 (https=)
BR (1) BRPI0821779A2 (https=)
CA (1) CA2710377A1 (https=)
CL (1) CL2008003901A1 (https=)
IL (1) IL206632A0 (https=)
MX (1) MX2010006991A (https=)
PE (1) PE20091180A1 (https=)
TW (1) TW200934784A (https=)
WO (1) WO2009086416A1 (https=)
ZA (1) ZA201004403B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
AU2008345097A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
CA2750639A1 (en) * 2009-01-23 2010-07-29 Cancer Research Technology Limited Hedgehog pathway inhibitors
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
US20120010230A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
RU2492855C2 (ru) * 2011-02-15 2013-09-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" СО РАМН (ФГБУ "НИИ онкологии" СО РАМН) Способ комбинированного лечения немелкоклеточного рака легкого ii и iii стадии с пред- и послеоперационной химиотерапией
CA2752008A1 (en) * 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
CN113552350B (zh) * 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
CA2988289C (en) 2015-06-04 2023-12-05 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN107137406B (zh) * 2016-03-01 2021-07-02 江苏恒瑞医药股份有限公司 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途
IL303436A (en) * 2016-08-10 2023-08-01 Celgene Quanticel Res Inc Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
JP2021516262A (ja) 2018-07-31 2021-07-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果
TWI725488B (zh) * 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
CA3094449C (en) 2018-07-31 2023-02-28 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CN115282133A (zh) * 2021-12-06 2022-11-04 温州医科大学 竹红菌乙素在制备抗结肠癌药物中的应用
AU2024207913A1 (en) * 2023-01-12 2025-07-31 Sol-Gel Technologies Ltd. Treatment and prevention of basal cell carcinoma with topical composition comprising patidegib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026430A2 (en) * 2004-08-27 2006-03-09 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
JP2010514796A (ja) * 2006-12-28 2010-05-06 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミン類似体

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US6238876B1 (en) * 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
JP2002522505A (ja) * 1998-08-13 2002-07-23 ユニヴァースティ オブ サザーン カリフォルニア 虚血組織への血流を増加させる方法
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20070021493A1 (en) * 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2386190C (en) * 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
US6552016B1 (en) * 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
IL133809A0 (en) * 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
US6613798B1 (en) * 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
US7708998B2 (en) * 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
AU2002247847A1 (en) * 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
JP2003192919A (ja) * 2001-10-17 2003-07-09 Asahi Denka Kogyo Kk 難燃性合成樹脂組成物
GB0221539D0 (en) * 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2005013800A2 (en) * 2003-07-15 2005-02-17 The Johns Hopkins University Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
US20070231828A1 (en) * 2003-10-01 2007-10-04 Johns Hopkins University Methods of predicting behavior of cancers
WO2005032343A2 (en) * 2003-10-01 2005-04-14 The Johns Hopkins University Hedgehog signaling in prostate regeneration neoplasia and metastasis
US20080057071A1 (en) * 2003-10-20 2008-03-06 Watkins David N Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
JP2008514726A (ja) * 2004-09-30 2008-05-08 ザ ユニヴァーシティー オヴ シカゴ ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
AU2006249199A1 (en) * 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2636596A1 (en) * 2005-11-04 2007-05-18 James Pluda Method of treating cancers with saha and pemetrexed
US20090263317A1 (en) * 2005-12-15 2009-10-22 Wei Chen Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease
US20070179091A1 (en) * 2005-12-27 2007-08-02 Genentech, Inc. Hedgehog Kinases and Their Use in Modulating Hedgehog Signaling
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2007123511A2 (en) * 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
CN103435694A (zh) * 2006-10-31 2013-12-11 美国政府卫生与公共服务部 Smoothened多肽及使用方法
WO2008057497A2 (en) * 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
NZ579356A (en) * 2007-03-07 2012-04-27 Infinity Pharmaceuticals Inc Cyclopamine lactam analogs and methods of use thereof
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
CA2683946C (en) * 2007-04-18 2013-01-22 Merck & Co., Inc. Triazole derivatives which are smo antagonists
US7867492B2 (en) * 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
CA2709203A1 (en) * 2007-12-13 2009-06-18 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
US20100222287A1 (en) * 2007-12-27 2010-09-02 Mcgovern Karen J Therapeutic Cancer Treatments
AU2008345097A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CL2009001479A1 (es) * 2008-07-02 2010-01-04 Infinity Pharmaceuticals Inc Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
US20120010230A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026430A2 (en) * 2004-08-27 2006-03-09 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
JP2010514796A (ja) * 2006-12-28 2010-05-06 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミン類似体
JP2010514797A (ja) * 2006-12-28 2010-05-06 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミン類似体の使用方法

Also Published As

Publication number Publication date
CL2008003901A1 (es) 2009-07-24
IL206632A0 (en) 2010-12-30
PE20091180A1 (es) 2009-08-26
KR20100137416A (ko) 2010-12-30
MX2010006991A (es) 2010-09-30
EP2225254A1 (en) 2010-09-08
TW200934784A (en) 2009-08-16
CN101918420A (zh) 2010-12-15
ZA201004403B (en) 2012-02-29
AU2008345151A1 (en) 2009-07-09
CA2710377A1 (en) 2009-07-09
AR070047A1 (es) 2010-03-10
US20090181997A1 (en) 2009-07-16
BRPI0821779A2 (pt) 2019-09-24
EP2225254A4 (en) 2011-03-30
WO2009086416A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
JP2011522773A (ja) 治療剤での癌の処置方法
US20100297118A1 (en) Therapeutic Cancer Treatments
US12533390B2 (en) Methods and compositions for treatment of Endothelin B receptor expressing tumors
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
US20100222287A1 (en) Therapeutic Cancer Treatments
EP2502078A1 (en) Methods and compositions for treating hedgehog-associated cancers
HK1221408A1 (zh) 用於治疗成胶质细胞瘤的组合疗法
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
KR20200026969A (ko) 치료제의 비경구 투여를 위한 조성물
CN106660950A (zh) Cxcr2拮抗剂用于预防和/或治疗化疗诱导的周围神经病变(cipn)的用途
JP2017536356A (ja) 肺の非小細胞癌及び多形性膠芽腫を処置するための放射線療法と一緒のジアンヒドロガラクチトール
KR20170078811A (ko) 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
TW201722422A (zh) 用於治療癌症之合理組合療法
US20200289495A1 (en) Methods of inhibiting endothelin b receptor expressing tumor metastases
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
US20200268829A1 (en) Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer
TW202434251A (zh) 治療癌症之療法
US20260115251A1 (en) Methods and compositions for treatment of endothelin b receptor expressing tumors
US20150258139A1 (en) Methods for treatment of cancer using lipoplatin
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131119